Lab Information
Inés Colmegna (MD)
ScientistCentre for Translational Biology
Department of Medicine (McGill)
Research Profile
Keywords
Rheumatology • arthritis • vaccine responses in rheumatology patients • stem and progenitor cells • aging • immunologyResearch Interests
My research focuses on evaluating the mechanisms underlying the development and perpetuation of the most common form of inflammatory polyarthritis: rheumatoid arthritis. Specifically, my group studies the impact of aging on human immune and stem/progenitor cell function. This will help in understanding the interplay of aging with immune tolerance and the risk of developing autoimmune disorders. In addition, we are interested in evaluating how protective responses generated by vaccines can be enhanced in people with rheumatologic conditions. This will help in reducing the morbidity and mortality of vaccine preventable diseases in this vulnerable group.Team Members
| Name | Position |
|---|
Latest Publications
- Nguyen, N., Bernatsky, S., Colmegna, I., Berger, C., Carrier, N., Allard-Chamard, H., Liang, P., Roux, S., Boire, G. & Hudson, M. (2025). Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Using an Extended Set of Clinical Variables: An Unmet Need. International journal of rheumatic diseases, vol. 28, p. e70281.
- Hitchon, C. A., Scuccimarri, R., Colmegna, I., Masaisa, F., Mody, G. M., Meltzer, M. & Rheumatology For All Rwanda Program Group (2025). Implementation and evaluation of a virtual rheumatology training program in East Africa. The Journal of rheumatology.
- Lora, M., Ménard, H. A., Nijnik, A., Langlais, D., Hudson, M. & Colmegna, I. (2025). Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells. Clinical and translational science, vol. 18, p. e70233.
- Tan, J., Bernatsky, S., Lee, J. L. F., Fortin, P. R., Dayam, R. M., Gingras, A.-C., Colmegna, I., Bowdish, D. M. E., Berger, C., Chan, D., Larché, M. J., Richards, D. P., Gonzalez Arreola, L., Hitchon, C. A., Lalonde, N. & Aviña-Zubieta, J. A. (2025). COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study. Vaccines, vol. 13.
- Ladouceur, A., Jamal, S., Saltman, A., Himmel, M., Hudson, M., Pope, J., Hoa, S., Roberts, J., Colmegna, I., Arreola, L. G., Nevskaya, T., Karmali, A., Moon, D., Schmidt, E., Toban, N., Cho, L., Barnetche, T. & Ye, C. (2025). Chronicity of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno-Oncology Database. ACR open rheumatology, vol. 7, p. e70002.
- Lu, J., Vulesevic, B., Burchell, A. N., Singer, J., Needham, J., Yang, Y., Qian, H., Chambers, C., Samji, H., Colmegna, I., Del Canto, S., Godin, G.-H., Habanyama, M., Hui, S. S. C., Kroch, A., Mandarino, E., Margolese, S., Martin, C., Owino, M., Lau, E., Mohammadi, T., Zhang, W., Pelaez, S., Kovacs, C., Benko, E., Cooper, C. L., Anis, A. H., Costiniuk, C. T. & COVAXHIV Study Group (2024). Sex differences in COVID-19 vaccine confidence in people living with HIV in Canada. Vaccine: X, vol. 21, p. 100566.
- Hitchon, C. A., Bowdish, D. M. E., Boire, G., Fortin, P. R., Flamand, L., Chandran, V., Dayam, R. M., Gingras, A.-C., Card, C. M., Colmegna, I., Larché, M. J., Kaplan, G. G., Lukusa, L., Lee, J. L. F., Bernatsky, S. & (2024). Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study. Vaccines, vol. 12.
- Tsyruk, O., Kaplan, G. G., Fortin, P. R., Hitchon, C. A., Chandran, V., Larché, M. J., Avina-Zubieta, A., Boire, G., Colmegna, I., Lacaille, D., Lalonde, N., Proulx, L., Richards, D. P., Boivin, N., DeBow, C., Kovalova-Wood, L., Paleczny, D., Wilhelm, L., Lukusa, L., Pereira, D., Lee, J. L., Bernatsky, S. & (2024). How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study. Vaccines, vol. 12.
- Brizio, M., Mancini, M., Lora, M., Joy, S., Zhu, S., Brilland, B., Reinhardt, D. P., Farge, D., Langlais, D. & Colmegna, I. (2024). Cytokine priming enhances the antifibrotic effects of human adipose derived mesenchymal stromal cells conditioned medium. Stem cell research & therapy, vol. 15, p. 329.
- Habib, R., Dayam, R. M., Hitchon, C., Chandran, V., Fortin, P. R., Boire, G., Bowdish, D. M. E., Gingras, A.-C., Flamand, L., Larché, M. J., Colmegna, I., Lukusa, L., Lee, J. L. F., Pereira, D., Bernstein, C. N., Lalonde, N., Turnbull, E., Bernatsky, S. & SUCCEED investigative team (2024). Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study. ACR open rheumatology, vol. 6, p. 581-586.
See also
